Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma

Growth Factor ◽

Immune Checkpoint ◽

Cutaneous Melanoma ◽

Immune Checkpoint Inhibitors ◽

Checkpoint Inhibitors ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Treatment strategy for myocarditis in patients using immune checkpoint inhibitors or combined anti-vascular endothelial growth factor therapy by clinical severity

European Journal of Cancer ◽

10.1016/j.ejca.2021.07.023 ◽

2021 ◽

Vol 157 ◽

pp. 10-20

Author(s):

Qing Liu ◽

Yiyi Yu ◽

Jinyi Lin ◽

Yan Wang ◽

Luoyan Ai ◽

...

Keyword(s):

Growth Factor ◽

Immune Checkpoint ◽

Immune Checkpoint Inhibitors ◽

Checkpoint Inhibitors ◽

Clinical Severity ◽

Vascular Endothelial ◽

Factor Therapy ◽

Growth Factor Therapy ◽

Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors

Annals of Oncology ◽

10.1093/annonc/mdv144 ◽

2015 ◽

Vol 26 (6) ◽

pp. 1230-1237 ◽

Cited By ~ 42

Author(s):

E.G. Chiorean ◽

H.I. Hurwitz ◽

R.B. Cohen ◽

J.D. Schwartz ◽

R.P. Dalal ◽

...

Keyword(s):

Monoclonal Antibody ◽

Growth Factor ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Advanced Solid Tumors ◽

Phase 1 study of weekly anti-vascular endothelial growth factor receptor-1 (VEGFR-1) monoclonal antibody IMC-18F1 in patients with advanced solid malignancies

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.14630 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 14630-14630 ◽

Cited By ~ 6

Author(s):

S. S. Krishnamurthi ◽

P. M. LoRusso ◽

P. H. Goncalves ◽

F. Fox ◽

E. K. Rowinsky ◽

...

Keyword(s):

Monoclonal Antibody ◽

Growth Factor ◽

Phase 1 ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Phase 1 Study ◽

Solid Malignancies ◽

Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody, is associated with inhibition of tumor angiogenesis

mAbs ◽

10.1080/19420862.2015.1086854 ◽

2015 ◽

Vol 7 (6) ◽

pp. 1195-1204 ◽

Author(s):

Dong Geon Kim ◽

Younggeon Jin ◽

Juyoun Jin ◽

Heekyoung Yang ◽

Kyeung Min Joo ◽

...

Keyword(s):

Monoclonal Antibody ◽

Growth Factor ◽

Anticancer Activity ◽

Tumor Angiogenesis ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding

Oncotarget ◽

10.18632/oncotarget.12108 ◽

2016 ◽

Vol 7 (45) ◽

pp. 72868-72885 ◽

Author(s):

Grazia Graziani ◽

Federica Ruffini ◽

Lucio Tentori ◽

Manuel Scimeca ◽

Annalisa S. Dorio ◽

...

Keyword(s):

Monoclonal Antibody ◽

Growth Factor ◽

Antitumor Activity ◽

Ligand Binding ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Phase I study of epidermal growth factor receptor (EGFR) inhibitor, erlotinib, and vascular endothelial growth factor monoclonal antibody, bevacizumab, in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.5539 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 5539-5539 ◽

Author(s):

A. M. Mauer ◽

E. E. W. Cohen ◽

S. J. Wong ◽

M. Kozloff ◽

J. Winegarden ◽

...

Keyword(s):

Monoclonal Antibody ◽

Growth Factor ◽

Phase I Study ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Egfr Inhibitor ◽

Metastatic Squamous Cell Carcinoma ◽

Epidermal Growth ◽

Phase I trial and pharmacokinetic study of Tanibirumab, a fully human monoclonal antibody to the vascular endothelial growth factor receptor 2 in patients with refractory solid tumors.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.2522 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 2522-2522 ◽

Cited By ~ 1

Author(s):

Su Jin Lee ◽

Jun Soo Ham ◽

Hee Kyung Kim ◽

Seonggyu Byeon ◽

Seon Young Lee ◽

...

Keyword(s):

Monoclonal Antibody ◽

Growth Factor ◽

Phase I ◽

Pharmacokinetic Study ◽

Phase I Trial ◽

Human Monoclonal Antibody ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors

Investigational New Drugs ◽

10.1007/s10637-017-0463-y ◽

2017 ◽

Vol 35 (6) ◽

pp. 782-790 ◽

Author(s):

Su Jin Lee ◽

Seon Young Lee ◽

Weon Sup Lee ◽

Jin San Yoo ◽

Jong-Mu Sun ◽

...

Keyword(s):

Monoclonal Antibody ◽

Growth Factor ◽

Phase I ◽

Pharmacokinetic Study ◽

Phase I Trial ◽

Human Monoclonal Antibody ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells

Journal of Experimental & Clinical Cancer Research ◽

10.1186/s13046-017-0577-2 ◽

2017 ◽

Vol 36 (1) ◽

Cited By ~ 18

Author(s):

Maria Grazia Atzori ◽

Lucio Tentori ◽

Federica Ruffini ◽

Claudia Ceci ◽

Lucia Lisi ◽

...

Keyword(s):

Stem Cells ◽

Monoclonal Antibody ◽

Growth Factor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Glioblastoma Stem Cells ◽

Human Glioblastoma ◽

Tanibirumab (TTAC-0001): A fully human monoclonal antibody targets vascular endothelial growth factor receptor 2 (VEGFR-2)

Archives of Pharmacal Research ◽

10.1007/s12272-011-0821-9 ◽

2011 ◽

Vol 34 (8) ◽

pp. 1223-1226 ◽

Cited By ~ 15

Author(s):

Sang Hoon Lee

Keyword(s):

Monoclonal Antibody ◽

Growth Factor ◽

Human Monoclonal Antibody ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽